NDA Group

Welcome to NDA Group

Europe’s leading regulatory drug development, pharmacovigilance and HTA consultancy

We support life science companies all over the world and across all phases of development, from pre-clinical to post marketing, to the needs and requirements of regulators and payers alike. We work together with our clients to address key strategic regulatory and reimbursement challenges. Our scientific expertise covers all major therapeutic areas.

The advice you get from NDA is from real experts in the industry, many who have been involved in shaping today’s regulatory, HTA and pharmacovigilance environment. We have close to 100 employees across Europe. More than 25% are ex EU regulators.

With our support, you can cut the time and associated cost it takes to get your products to market, and keep them there.

NDA supported more than 38% of the new medicinal products that were approved in the EU in 2014.

More +
and Quality
More +
Health Technology
More +
NDA Advisory
More +

Expert Spotlight

Professor Ken Paterson   |   HTA Advisory Board Member

More +
Professor Ken Paterson How Ken can help your Business

Ken can assist in developing clinical investigation programmes to meet the needs of health technology assessment (HTA) and reimbursement bodies as well as regulators, and in translating clinical trial efficacy into patient-centred clinical value. His combination of wide-ranging clinical expertise and health economic experience is unusual and allows him to offer insightful analysis and advice. This may be particularly useful where the needs of regulators and HTA are perceived to be different but may actually be reconcilable.

More +

Latest News from NDA

  • Steffen A European View on Biosimilars with a Global Outlook
    Professor Steffen Thirstrup, Director of NDA Regulatory Advisory Board, chairs the Biosimilars Conference in London betw… Read more
    fipawards1 Dr. Lönngren receives Award at the FIP Congress
    Dr. Thomas Lönngren, Strategic Advisor to NDA Group and former Executive Director of the European Medicines Agency (EMA)… Read more
    JMK_3876 Prepare on your journey to compliance & inspections readiness excellence
    Shelley Gandhi, NDA Group Strategic Adviser Pharmacovigilance & Drug Safety, is the prominent trainer at the Pharmac… Read more
  • Markku Dr Toivonen writes about Prevention and Treatment of Alzheimer’s Disease
    Dr Markku Toivonen, NDA Scientific Director and Advisory Board member, has written an article titled "Industry and Acade… Read more
    Pieter_Neels NDA's Dr Pieter Neels is invited to WHO working group meeting in Geneva
    Dr Pieter Neels, NDA Advisory Board member, is attending WHO working group meeting on the development of guidelines on l… Read more
    JMK_3958 NDA's Nora Sjödin speaks at Market Access event in Lund and Stockholm
    NDA Principal Consultant, Nora Sjödin is going to be speaking at Lyckad Läkemedelsutveckling on 24th September (in Lund)… Read more
We make sure that men, women and children all over the world get access
to the best possible medicines without unnecessary delay.